JP2012509071A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509071A5 JP2012509071A5 JP2011536741A JP2011536741A JP2012509071A5 JP 2012509071 A5 JP2012509071 A5 JP 2012509071A5 JP 2011536741 A JP2011536741 A JP 2011536741A JP 2011536741 A JP2011536741 A JP 2011536741A JP 2012509071 A5 JP2012509071 A5 JP 2012509071A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid construct
- invariant chain
- protein
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200801638 | 2008-11-21 | ||
| DKPA200801638 | 2008-11-21 | ||
| PCT/DK2009/050310 WO2010057501A1 (en) | 2008-11-21 | 2009-11-20 | Priming of an immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014226711A Division JP2015061530A (ja) | 2008-11-21 | 2014-11-07 | 免疫応答のプライミング |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012509071A JP2012509071A (ja) | 2012-04-19 |
| JP2012509071A5 true JP2012509071A5 (enExample) | 2013-01-24 |
Family
ID=40823418
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536741A Pending JP2012509071A (ja) | 2008-11-21 | 2009-11-20 | 免疫応答のプライミング |
| JP2014226711A Pending JP2015061530A (ja) | 2008-11-21 | 2014-11-07 | 免疫応答のプライミング |
| JP2017011749A Pending JP2017131220A (ja) | 2008-11-21 | 2017-01-26 | 免疫応答のプライミング |
| JP2019091809A Active JP6825036B2 (ja) | 2008-11-21 | 2019-05-15 | 免疫応答のプライミング |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014226711A Pending JP2015061530A (ja) | 2008-11-21 | 2014-11-07 | 免疫応答のプライミング |
| JP2017011749A Pending JP2017131220A (ja) | 2008-11-21 | 2017-01-26 | 免疫応答のプライミング |
| JP2019091809A Active JP6825036B2 (ja) | 2008-11-21 | 2019-05-15 | 免疫応答のプライミング |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20110293704A1 (enExample) |
| EP (3) | EP3552622A3 (enExample) |
| JP (4) | JP2012509071A (enExample) |
| CN (3) | CN102292102A (enExample) |
| AU (1) | AU2009317691A1 (enExample) |
| BR (1) | BRPI0921927B8 (enExample) |
| CA (1) | CA2743229A1 (enExample) |
| CY (1) | CY1122117T1 (enExample) |
| DK (1) | DK2865387T3 (enExample) |
| ES (1) | ES2743677T3 (enExample) |
| HK (1) | HK1209645A1 (enExample) |
| HR (1) | HRP20191594T1 (enExample) |
| HU (1) | HUE045093T2 (enExample) |
| IL (4) | IL212914A0 (enExample) |
| LT (1) | LT2865387T (enExample) |
| PL (1) | PL2865387T3 (enExample) |
| PT (1) | PT2865387T (enExample) |
| RU (2) | RU2011125306A (enExample) |
| SI (1) | SI2865387T1 (enExample) |
| WO (1) | WO2010057501A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008219065B2 (en) | 2007-02-19 | 2014-01-30 | Marine Polymer Technologies, Inc. | Hemostatic compositions and therapeutic regimens |
| US9061066B2 (en) * | 2010-06-04 | 2015-06-23 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Immunoadjuvant compounds and uses thereof |
| GB201115095D0 (en) | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
| US20140348863A1 (en) * | 2011-10-12 | 2014-11-27 | Alessia Bianchi | Cmv antigens and uses thereof |
| PT2788767T (pt) | 2011-12-07 | 2017-12-06 | Belgian Volition Sprl | Método de detecção de adutos de nucleosoma |
| BR112015001390B1 (pt) * | 2012-07-26 | 2024-04-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc | Proteína de fusão, ácido nucleico isolado e uso de uma composição de vacina |
| WO2014139587A1 (en) | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
| HK1220626A1 (zh) | 2013-03-15 | 2017-05-12 | The Centre For Drug Research And Development | 具细胞毒性和抗有丝分裂的化合物以及其使用方法 |
| US10576143B2 (en) | 2013-03-15 | 2020-03-03 | Glaxosmithkline Biologicals Sa | Poxviral vaccines |
| KR102354389B1 (ko) * | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
| GB201321384D0 (en) * | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
| WO2015095953A1 (en) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Sulfonamide-containing linkage systems for drug conjugates |
| BR112016015105A8 (pt) * | 2013-12-27 | 2018-04-24 | Var2 Pharmaceuticals Aps | conjugados var2csa-droga |
| ES2905569T3 (es) | 2014-09-17 | 2022-04-11 | Zymeworks Inc | Compuestos citotóxicos y antimitóticos y métodos para utilizarlos |
| WO2017025782A1 (en) | 2014-09-17 | 2017-02-16 | Glaxosmithkline Biologicals Sa | Improved poxviral vaccines |
| MX2018004544A (es) | 2015-10-12 | 2018-11-09 | Nantomics Llc | Composiciones y métodos para los neoepítopos de cáncer viral. |
| ES2970865T3 (es) | 2015-12-16 | 2024-05-31 | Gritstone Bio Inc | Identificación, fabricación y uso de neoantígenos |
| EP3504230A1 (en) | 2016-08-23 | 2019-07-03 | GlaxoSmithKline Biologicals SA | Fusion peptides with antigens linked to short fragments of invariant chain (cd74) |
| WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
| GB201620968D0 (en) | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
| GB201704417D0 (en) | 2017-03-20 | 2017-05-03 | Univ Copenhagen | Improved li vaccine adjuvant |
| JP7298926B2 (ja) * | 2017-07-12 | 2023-06-27 | ノイスコム アーゲー | 癌の治療のためのネオアンチゲンワクチン組成物 |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| KR102747530B1 (ko) * | 2017-11-03 | 2024-12-27 | 노우스콤 아게 | 백신 t 세포 인핸서 |
| CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
| GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
| GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
| CN108285885A (zh) * | 2017-12-28 | 2018-07-17 | 中国农业大学 | 一种霍乱弧菌菌影制备方法及其在家禽疫苗中的应用 |
| EP3807298A1 (en) | 2018-06-12 | 2021-04-21 | GlaxoSmithKline Biologicals S.A. | Adenovirus polynucleotides and polypeptides |
| US12576143B2 (en) | 2018-10-19 | 2026-03-17 | Nouscom Ag | Teleost invariant chain cancer vaccine |
| EP3897846A1 (en) | 2018-12-21 | 2021-10-27 | GlaxoSmithKline Biologicals SA | Methods of inducing an immune response |
| RU2725493C2 (ru) * | 2018-12-28 | 2020-07-02 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Система для стабильной экспрессии опухоль-ассоциированных антигенов на основе лентивирусного вектора |
| CA3132601A1 (en) | 2019-03-05 | 2020-09-10 | Glaxosmithkline Biologicals Sa | Hepatitis b immunisation regimen and compositions |
| CN111729093B (zh) * | 2020-06-29 | 2022-05-24 | 南京超维景生物科技有限公司 | 一种造影剂成膜剂组合物、造影剂成膜脂液、造影剂及其制备方法 |
| EP4137153A1 (en) | 2021-08-18 | 2023-02-22 | Sirion Biotech GmbH | Therapeutic papilloma virus vaccines |
| WO2024133160A1 (en) | 2022-12-19 | 2024-06-27 | Glaxosmithkline Biologicals Sa | Hepatitis b compositions |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US587673A (en) | 1897-08-03 | higgins | ||
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| JP2682061B2 (ja) | 1988-10-07 | 1997-11-26 | 藤沢薬品工業株式会社 | ペプチドの分子内ジスルフィド結合の形成法 |
| US5559028A (en) * | 1993-05-19 | 1996-09-24 | Antigen Express, Inc. | Methods of enhancing or antigen presentation to T cells inhibiting |
| US5876735A (en) | 1994-04-22 | 1999-03-02 | Corixa Corporation | Methods for enhancement of protective immune responses |
| AU7690896A (en) * | 1995-09-14 | 1997-04-01 | Universitat Tubingen | Recombinant polypeptide based on the primary sequence of the invariant chain with at least one primary sequence of a specific t-cell epitope or a protein derivative and nucleic acids coding for this recombinant polypeptide |
| AU3307497A (en) * | 1996-06-26 | 1998-01-14 | Antigen Express, Inc. | Immunotherapy by modulation of antigen presentation |
| US6534482B1 (en) * | 1998-05-13 | 2003-03-18 | Epimmune, Inc. | Expression vectors for stimulating an immune response and methods of using the same |
| US6432409B1 (en) * | 1999-09-14 | 2002-08-13 | Antigen Express, Inc. | Hybrid peptides modulate the immune response |
| US20030235594A1 (en) * | 1999-09-14 | 2003-12-25 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| GB0208817D0 (en) | 2002-04-17 | 2002-05-29 | European Molecular Biology Lab Embl | Method for producing monoclonal antibodies |
| US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| EP1957528B1 (en) | 2005-11-30 | 2012-11-07 | University of Copenhagen | A nucleotide vaccine |
| US20080095798A1 (en) | 2006-10-18 | 2008-04-24 | Robert Humphreys | Ii-key enhanced vaccine potency |
| US9085638B2 (en) * | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
| EP2344191A4 (en) * | 2008-09-02 | 2013-02-13 | Antigen Express Inc | HUMAN PAPILLOMAVIRUS / LI-KEY HYBRIDS AND METHODS OF USE |
-
2009
- 2009-11-20 EP EP19173464.9A patent/EP3552622A3/en active Pending
- 2009-11-20 BR BRPI0921927A patent/BRPI0921927B8/pt active Search and Examination
- 2009-11-20 JP JP2011536741A patent/JP2012509071A/ja active Pending
- 2009-11-20 WO PCT/DK2009/050310 patent/WO2010057501A1/en not_active Ceased
- 2009-11-20 SI SI200931996T patent/SI2865387T1/sl unknown
- 2009-11-20 EP EP15152408.9A patent/EP2865387B1/en active Active
- 2009-11-20 CN CN2009801549244A patent/CN102292102A/zh active Pending
- 2009-11-20 AU AU2009317691A patent/AU2009317691A1/en not_active Abandoned
- 2009-11-20 HU HUE15152408A patent/HUE045093T2/hu unknown
- 2009-11-20 CN CN201710007117.6A patent/CN107090472A/zh active Pending
- 2009-11-20 RU RU2011125306/10A patent/RU2011125306A/ru unknown
- 2009-11-20 LT LTEP15152408.9T patent/LT2865387T/lt unknown
- 2009-11-20 PL PL15152408T patent/PL2865387T3/pl unknown
- 2009-11-20 CA CA2743229A patent/CA2743229A1/en active Pending
- 2009-11-20 RU RU2017138373A patent/RU2017138373A/ru not_active Application Discontinuation
- 2009-11-20 US US13/129,857 patent/US20110293704A1/en not_active Abandoned
- 2009-11-20 DK DK15152408.9T patent/DK2865387T3/da active
- 2009-11-20 PT PT15152408T patent/PT2865387T/pt unknown
- 2009-11-20 ES ES15152408T patent/ES2743677T3/es active Active
- 2009-11-20 CN CN201410485599.2A patent/CN104404068A/zh active Pending
- 2009-11-20 EP EP09760468A patent/EP2355842A1/en not_active Withdrawn
-
2011
- 2011-05-16 IL IL212914A patent/IL212914A0/en unknown
-
2014
- 2014-06-16 IL IL233175A patent/IL233175A0/en unknown
- 2014-06-16 IL IL233174A patent/IL233174A0/en unknown
- 2014-06-16 IL IL233176A patent/IL233176A0/en unknown
- 2014-09-10 US US14/482,452 patent/US20150056227A1/en not_active Abandoned
- 2014-11-07 JP JP2014226711A patent/JP2015061530A/ja active Pending
-
2015
- 2015-10-28 HK HK15110589.9A patent/HK1209645A1/en unknown
-
2017
- 2017-01-26 JP JP2017011749A patent/JP2017131220A/ja active Pending
- 2017-04-25 US US15/496,045 patent/US20170290898A1/en not_active Abandoned
-
2019
- 2019-05-15 JP JP2019091809A patent/JP6825036B2/ja active Active
- 2019-09-02 CY CY20191100920T patent/CY1122117T1/el unknown
- 2019-09-04 HR HRP20191594 patent/HRP20191594T1/hr unknown
-
2021
- 2021-06-17 US US17/350,971 patent/US20210386842A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012509071A5 (enExample) | ||
| RU2011125306A (ru) | Праймирование иммунного ответа | |
| JP6321261B2 (ja) | ワクチン組成物及びその使用方法 | |
| An et al. | Silica nanoparticle as a lymph node targeting platform for vaccine delivery | |
| Abdullah et al. | Supramolecular self-assembled peptide-based vaccines: current state and future perspectives | |
| Li et al. | Rational design of T-cell-and B-cell-based therapeutic cancer vaccines | |
| RU2712743C2 (ru) | Вакцина против бешенства | |
| Andrianov et al. | Molecular-level interactions of polyphosphazene immunoadjuvants and their potential role in antigen presentation and cell stimulation | |
| CA3036742A1 (en) | Modified vsv-g and vaccines thereof | |
| AU2016379413A1 (en) | Covalent polymer-antigen conjugated particles | |
| Wang et al. | Cell penetrating peptide-based redox-sensitive vaccine delivery system for subcutaneous vaccination | |
| US20040033585A1 (en) | Flexible vaccine assembly and vaccine delivery platform | |
| Bolhassani et al. | DNA immunization as an efficient strategy for vaccination | |
| WO2022043449A1 (en) | Vaccines based on an antigen protein fused to a nanostructuring scaffold | |
| Mbatha et al. | Future prospects in mRNA vaccine development | |
| JP5458286B1 (ja) | 樹状細胞表面タンパク質に対する抗体を有するバイオナノカプセル | |
| Bae et al. | Potential of translationally controlled tumor protein-derived protein transduction domains as antigen carriers for nasal vaccine delivery | |
| JP5901084B2 (ja) | ペプチドアジュバント | |
| CN118576725A (zh) | 一种以arc蛋白为载体的纳米颗粒及其制备方法和应用 | |
| WO2005091753A2 (en) | Flexible vaccine assembly and vaccine delivery platform | |
| US20050282263A1 (en) | Flexible vaccine assembly and vaccine delivery platform | |
| JP2025514872A5 (enExample) | ||
| WO2020257315A1 (en) | Multiple antigen protein displayed adjuvant systems | |
| CN103747799A (zh) | 细胞毒性t细胞诱导剂 | |
| Park | Development and Immunological Evaluation of Protein-Based Nanoparticle Vaccines |